Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's

Trial StartMivelsiranPositive

AI Analysis

Summary

Alnylam announced the initiation of a mid-stage study of Mivelsiran in Down Syndrome-Associated Alzheimer's disease, expanding its development program in neurodegenerative conditions.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.40

trial initiationmid-stageneurologyrare disease

Related Companies

$ALNY

Read the original article

Published by yahoo_finance on July 15, 2026 10:34 AM

Read Original